Oakbrook Investments LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 91.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,200 shares of the medical research company’s stock after buying an additional 1,050 shares during the period. Oakbrook Investments LLC’s holdings in Bio-Rad Laboratories were worth $672,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its holdings in Bio-Rad Laboratories by 113.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,582 shares of the medical research company’s stock worth $789,000 after buying an additional 1,373 shares during the last quarter. Retirement Systems of Alabama lifted its holdings in Bio-Rad Laboratories by 0.4% during the 1st quarter. Retirement Systems of Alabama now owns 26,213 shares of the medical research company’s stock worth $8,013,000 after buying an additional 105 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in Bio-Rad Laboratories by 1.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 5,400 shares of the medical research company’s stock worth $1,651,000 after buying an additional 100 shares during the last quarter. Virtu Financial LLC bought a new position in Bio-Rad Laboratories during the 1st quarter worth approximately $1,655,000. Finally, First Citizens Bank & Trust Co. lifted its holdings in Bio-Rad Laboratories by 38.0% during the 1st quarter. First Citizens Bank & Trust Co. now owns 1,720 shares of the medical research company’s stock worth $526,000 after buying an additional 474 shares during the last quarter. 63.63% of the stock is currently owned by institutional investors.
Shares of Bio-Rad Laboratories stock opened at $294.13 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.19 and a current ratio of 4.49. The company has a market cap of $8.76 billion, a PE ratio of 50.36, a P/E/G ratio of 2.74 and a beta of 1.27. Bio-Rad Laboratories, Inc. has a twelve month low of $220.05 and a twelve month high of $345.15.
A number of research analysts have commented on BIO shares. Deutsche Bank increased their target price on Bio-Rad Laboratories from $330.00 to $350.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Barclays raised Bio-Rad Laboratories from an “equal weight” rating to an “overweight” rating and set a $315.00 target price on the stock in a report on Thursday, January 3rd. Finally, Zacks Investment Research raised Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Friday, February 22nd. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $359.17.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
See Also: Dividend Achievers
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.